title: [Treatment of Gastroenteropancreatic Neuroendocrine Tumors with 177Lu-DOTA-TATE: Experience of the Portuguese Institute of Oncology in Porto].
abstract: BACKGROUND
  The purpose of this article is to report the experience of the Portuguese Institute of Oncology - Porto in the treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality.
  
  
  METHODS
  A retrospective analysis of clinical reports of patients with gastroenteropancreatic neuroendocrine tumors undergoing treatment with 177Lu-DOTA-TATE between April 2011 and November 2013 was performed.
  
  
  RESULTS
  Thirty six cases were reviewed and 30 completed all 3 cycles of 177Lu-DOTA-TATE (83.3%). In these patients it was registered: acute side effects in 8.9% of cycles; grade 3 CTCAE liver toxicity in 13.3% of patients (all with previous abnormal liver function); absence of significant renal or hematologic toxicity; symptomatic improvement in 71.4% of patients; median overall time to progression of 25.6 months; median overall survival from diagnosis of 121.7 months. Patients with higher expression of somatostatin receptors had longer progression-free survival and overall survival times (p < 0.05).
  
  
  CONCLUSIONS
  Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is an effective, safe and well-tolerated treatment, as evidenced in our study by the following findings: symptomatic improvement in most patients and increased time to disease progression and survival (especially in those with higher sstr expression), with acute and significant subacute/chronic side effects reported only in a minority of cases.
  
  
  CONCLUSIONS
  Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE is a promising treatment for patients with gastroenteropancreatic neuroendocrine tumors, with demonstrated benefits in terms of safety and efficacy.
authors.affiliation: Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Inês Lucena
authors.initials: IL
authors.lastname: Sampaio
authors.affiliation: Serviço de Endocrinologia. Hospital Garcia de Orta. Almada. Portugal.
authors.forename: Henrique Vara
authors.initials: HV
authors.lastname: Luiz
authors.affiliation: Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Liliana Sobral
authors.initials: LS
authors.lastname: Violante
authors.affiliation: Serviço de Endocrinologia. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Ana Paula
authors.initials: AP
authors.lastname: Santos
authors.affiliation: Serviço de Epidemiologia. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Luís
authors.initials: L
authors.lastname: Antunes
authors.affiliation: Serviço de Endocrinologia. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Isabel
authors.initials: I
authors.lastname: Torres
authors.affiliation: Serviço de Cirurgia Geral. Instituto Português de Oncologia do Porto. Portugal.
authors.forename: Cristina
authors.initials: C
authors.lastname: Sanches
authors.affiliation: Serviço de Oncologia. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Isabel
authors.initials: I
authors.lastname: Azevedo
authors.affiliation: Serviço de Medicina Nuclear. Instituto Português de Oncologia. Porto. Portugal.
authors.forename: Hugo
authors.initials: H
authors.lastname: Duarte
mesh_terms: D006801:Humans; D007414:Intestinal Neoplasms; D018358:Neuroendocrine Tumors / Q000628:therapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000628:therapy*
chemical_list: D009942:Organometallic Compounds; C447941:lutetium Lu 177 dotatate; D015282:Octreotide
keywords: 177Lu-DOTATATE; Neoplasias Gastrointestinais; Neoplasias do Pâncreas; Tumores Neuroendócrinos.